The EMPACT-MI trial found that giving Boehringer Ingelheim and Eli Lilly’s SGLT2 drug Jardiance (empagliflozin) within 14 days of an acute myocardial infarction (AMI) reduced the risk of a ...
Boehringer and Eli Lilly have started a large-scale trial of their ... with a 15% mortality and 30% readmission rate within 60 to 90 days of being discharged. If Jardiance is shown to be effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback